HX009
Triple-Negative Breast Cancer (combination therapy)
Phase 2IND approved by NMPA and FDA
Key Facts
Indication
Triple-Negative Breast Cancer (combination therapy)
Phase
Phase 2
Status
IND approved by NMPA and FDA
Company
About HanX Biopharmaceuticals
Clinical-stage Chinese biotech developing novel antibody therapies for oncology and immunology with multiple IND approvals.
View full company profile